{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065680","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.424399+00:00","generated_at":"2026-05-22T07:40:17.789624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outset Medical Q1 revenue up 6%, gross margin expands to 37.2%, net loss narrows","bullets":["Net revenue $29.8M (+6% YoY); recurring Tablo consumables & services $22.7M (+20% YoY).","Gross margin 37.2% (non-GAAP 37.6%), up from 29.2% in Q1 2024; product margin 48.3%.","Net loss $25.8M (-$3.66/share) vs. $39.9M (-$11.77) a year ago; operating cash use down 44%.","Reiterated FY2025 guidance: revenue $115M-$125M, non-GAAP gross margin high-30% range, cash use < $50M.","Tariff exemption confirmed under USMCA and for chronically disabled; no expected impact."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065680","json":"https://secwatch.observer/filing/0000950170-25-065680.json","markdown":"https://secwatch.observer/filing/0000950170-25-065680.md","text":"https://secwatch.observer/filing/0000950170-25-065680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025065680/0000950170-25-065680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025065680/om-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:40:17.789624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}